{"id":4093,"date":"2008-12-22T14:16:42","date_gmt":"2008-12-22T22:16:42","guid":{"rendered":"http:\/\/www.carlsbadistan.com\/?p=4093"},"modified":"2008-12-22T16:32:54","modified_gmt":"2008-12-23T00:32:54","slug":"life-technologies-buys-visigen","status":"publish","type":"post","link":"http:\/\/www.carlsbadistan.com\/?p=4093","title":{"rendered":"Life Technologies Buys VisiGen"},"content":{"rendered":"<p>Compared to the deals we&#8217;ve been used to from <strong>Life Technologies<\/strong> (formerly known as <strong><a href=\"http:\/\/www.invitrogen.com\/site\/us\/en\/home.html\" target=\"_blank\">Invitrogen<\/a><\/strong>) their $20 million purchase of a Houston, Texas based <strong><a href=\"http:\/\/visigenbio.com\/\" target=\"_blank\">VisiGen Biotechnologies<\/a><\/strong> isn&#8217;t all that impressive. But it could be huge for Life and for the business of DNA sequencing.<\/p>\n<blockquote><p>Primary founder <strong>Susan Hardin<\/strong> remains at the helm as president and CEO, while the other five co-founders have chosen to stay at the university. . . . VisiGen has been developing a brainchild of Hardin \u2014 a radically new method of sequencing DNA that could achieve the goal of sequencing a human genome in one day at a cost of $1,000. A genome is the genetic code in a person\u2019s DNA.<\/p><\/blockquote>\n<p>According to a story in the Houston Business Journal the cost of sequencing the first DNA was $3 billion. So doing it for $1,000 would make it a little more widely accessible.<\/p>\n<p><strong>[Link: <\/strong><strong><a href=\"http:\/\/www.bizjournals.com\/houston\/stories\/2008\/12\/22\/story3.html?b=1229922000%5E1750176\" target=\"_blank\">Houston Business Journal<\/a><\/strong><strong>]<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Compared to the deals we&#8217;ve been used to from Life Technologies (formerly known as Invitrogen) their $20 million purchase of a Houston, Texas based VisiGen Biotechnologies isn&#8217;t all that impressive. But it could be huge for Life and for the business of DNA sequencing. Primary founder Susan Hardin remains at the helm as president and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[8,34,26],"tags":[],"_links":{"self":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts\/4093"}],"collection":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4093"}],"version-history":[{"count":2,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts\/4093\/revisions"}],"predecessor-version":[{"id":4095,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=\/wp\/v2\/posts\/4093\/revisions\/4095"}],"wp:attachment":[{"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4093"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4093"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.carlsbadistan.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4093"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}